Management of Systemic and Pulmonary Hypertension

  • P. Giomarelli
  • S. Scolletta
  • B. Biagioli
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)


Systemic hypertension is a very frequent condition in developed countries and therefore constitutes a common problem in the perioperative period. In the Unites States nearly 29% of adults in 1999 and 2000 were affected by hypertension (age-adjusted prevalence of hypertension): 30% of hypertensive individuals are not aware of their diagnosis, 59% are being treated for hypertension, and only 34% have a blood pressure below 140/90 mmHg [1, 2].


Nitric Oxide Pulmonary Hypertension Pulmonary Arterial Hypertension Primary Pulmonary Hypertension Hypertensive Crisis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hajjar I, Kotchen TA (2003) Trends in prevalence, awareness, treatment and control of hypertension in the United States 1999–2000. JAMA 290:199–206PubMedCrossRefGoogle Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR et al (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Latest guidelines for hypertension prevention and management. JAMA 289:2560–2572PubMedCrossRefGoogle Scholar
  3. 3.
    Nichols WW, O’Rourke MF (2005) McDonald’s blood flow in arteries: theoretical, experimental and clinical principles. Hodder Arnold, LondonGoogle Scholar
  4. 4.
    Wilkinson IB, Franklin SS, Hall IR et al (2001) Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. Hypertension 38:1461–1466PubMedGoogle Scholar
  5. 5.
    Karamanoglu M, O’Rourke MF, Avolio AP et al (1993) An analysis of the relationship between central aortic and peripheral upper limb pressure wave in man. Eur Heart J 14:160–167PubMedGoogle Scholar
  6. 6.
    Cecconi M, Wilson J, Rhodes A (2006) Pulse pressure analysis. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 176–184CrossRefGoogle Scholar
  7. 7.
    Giomarelli P, Biagioli B, Scolletta S (2004) Cardiac output monitoring by pressure recording analytical method in cardiac surgery. Eur J Cardiothorac Surg 26:515–520PubMedCrossRefGoogle Scholar
  8. 8.
    Reuter DA, Goetz AE (2005) Arterial pulse contour analysis: applicability to clinical routine. In: Pinsky MR, Payen D (eds) Functional Hemodynamic Monitoring. Springer, Berlin Heidelberg New York, pp 175–182CrossRefGoogle Scholar
  9. 9.
    Devereaux PJ, Leslie K (2004) Best evidence in anesthetic practice. Prevention: alpha2-and beta-adrenergic antagonists reduce perioperative cardiac events. Can J Anaesth 51:290–292PubMedCrossRefGoogle Scholar
  10. 10.
    Beilin LJ, Goldby FS, Mohring J (1977) High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension. Clin Sci Mol Med 52:111PubMedGoogle Scholar
  11. 11.
    Funakoshi Y, Ichiki T, Ito K et al (1999) Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 34:118–125PubMedGoogle Scholar
  12. 12.
    Muller DN, Dechend R, Mervaala EM et al (2000) NF-?B inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35:193–201PubMedGoogle Scholar
  13. 13.
    Gudbrandsson T, Hansson L, Herlitz H et al (1977) Immunological changes in patients with previous malignant essential hypertension. Am J Physiol 232:F26Google Scholar
  14. 14.
    Woods JW, Blythe WB, Huffines WD (1974) Management of malignant hypertension. N Engl J Med 291:10PubMedCrossRefGoogle Scholar
  15. 15.
    Varon J, Marik PE (2000) The diagnosis and management of hypertensive crisis. Chest 118:214–227PubMedCrossRefGoogle Scholar
  16. 16.
    Abdelwahab W, Frishman W, Landau A (1995) Management of hypertensive urgencies and emergencies. J Clin Pharm 35:747–762Google Scholar
  17. 17.
    Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary artery hypertension. N Engl J Med 351:1425–1436PubMedCrossRefGoogle Scholar
  18. 18.
    Humbert M, Morrel NW, Archer SL et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(suppl S):13S–24SPubMedCrossRefGoogle Scholar
  19. 19.
    Runo JR, Loyd JE (2003) Primary pulmonary hypertension. Lancet 361:1533–1544PubMedCrossRefGoogle Scholar
  20. 20.
    Deng Z, Morse JH, Slager SL et al (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737–744PubMedCrossRefGoogle Scholar
  21. 21.
    Hinderliter AL, Willis PW 4th, Barst RJ et al (1997) Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 95:1479–1486PubMedGoogle Scholar
  22. 22.
    Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT et al (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173–1174.PubMedCrossRefGoogle Scholar
  23. 23.
    Schrader BJ, Inbar S, Kaufmann L et al (1992) Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 19:1060–1064PubMedCrossRefGoogle Scholar
  24. 24.
    Fuster V, Steele PM, Edwards WD et al (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70:580–587PubMedGoogle Scholar
  25. 25.
    Sitbon O, Humber M, Ioos V et al (2003) Who benefits from long-term calciumchannel blocker therapy in primary pulmonary hypertension? Am J Resp Crit Care Med 167:440Google Scholar
  26. 26.
    Higenbottam T, Wheeldon D, Wells F et al (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1:1046–1047PubMedCrossRefGoogle Scholar
  27. 27.
    Shapiro SM, Oudiz RJ, Cao T et al (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30:343–349PubMedCrossRefGoogle Scholar
  28. 28.
    McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482PubMedCrossRefGoogle Scholar
  29. 29.
    Simonneau G, Barst RJ, Galie N et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804PubMedGoogle Scholar
  30. 30.
    Okano Y, Yoshioka T, Shimouki A et al (1997) Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 349:1365PubMedCrossRefGoogle Scholar
  31. 31.
    Galie N, Humbert M, Vachiery JL et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502PubMedCrossRefGoogle Scholar
  32. 32.
    Barst RJ, McGoon M, McLaughlin V et al (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125PubMedCrossRefGoogle Scholar
  33. 33.
    Rubin LJ, Badesch DB, Barst RJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903PubMedCrossRefGoogle Scholar
  34. 34.
    Channick RN, Simonneau G, Sitbon O et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123PubMedCrossRefGoogle Scholar
  35. 35.
    Ziegler JW, Ivy DD, Wiggins JW et al (1998) Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 158:1388–1395PubMedGoogle Scholar
  36. 36.
    Zhao L, Mason NA, Morrel NW et al (2001) Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424–428PubMedGoogle Scholar
  37. 37.
    Michelakis E, Tymchak W, Lien D et al (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398–2403PubMedCrossRefGoogle Scholar
  38. 38.
    Atz AM, Wessel DL (1999) Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91:307–310PubMedCrossRefGoogle Scholar
  39. 39.
    Kleinsasser A, Loekinger A, Hoermann C et al (2001) Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 163:339–343PubMedGoogle Scholar
  40. 40.
    Zapol WM, Falke KJ, Hurford WE et al (1994) Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. Chest 105:87S–91SPubMedGoogle Scholar
  41. 41.
    Kinsella JP, Neish SR, Shaffer E et al (1992) Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:819–820PubMedCrossRefGoogle Scholar
  42. 42.
    Christie JD, Kotloff RM, Pochettino A et al (2003) Clinical risk factors for primary graft failure following lung transplantation. Chest 124:1232–1241PubMedCrossRefGoogle Scholar
  43. 43.
    Bennett LE, Keck BM, Hertz MI et al (2001) Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international registry for thoracic organ transplantation. Clin Transpl 25–40Google Scholar
  44. 44.
    Pielsticker EJ, Martinez FJ, Rubenfire M (2001) Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 20:1297–1304PubMedCrossRefGoogle Scholar
  45. 45.
    Simonneau G, Galie N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12SPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • P. Giomarelli
    • 1
  • S. Scolletta
    • 1
  • B. Biagioli
    • 1
  1. 1.Department of Anesthesia and Intensive Care UnitUniversity of SienaItaly

Personalised recommendations